184 related articles for article (PubMed ID: 23068711)
1. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.
Nyflot MJ; Harari PM; Yip S; Perlman SB; Jeraj R
Radiother Oncol; 2012 Oct; 105(1):36-40. PubMed ID: 23068711
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.
Bradshaw TJ; Bowen SR; Jallow N; Forrest LJ; Jeraj R
J Nucl Med; 2013 Nov; 54(11):1931-7. PubMed ID: 24042031
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
5. Predicting location of recurrence using FDG, FLT, and Cu-ATSM PET in canine sinonasal tumors treated with radiotherapy.
Bradshaw T; Fu R; Bowen S; Zhu J; Forrest L; Jeraj R
Phys Med Biol; 2015 Jul; 60(13):5211-24. PubMed ID: 26083082
[TBL] [Abstract][Full Text] [Related]
6. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
Hansen AE; Kristensen AT; Law I; McEvoy FJ; Kjær A; Engelholm SA
Radiother Oncol; 2012 Mar; 102(3):424-8. PubMed ID: 22119225
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.
Clausen MM; Hansen AE; Af Rosenschold PM; Kjaer A; Kristensen AT; McEvoy FJ; Engelholm SA
Radiat Oncol; 2013 Nov; 8():262. PubMed ID: 24199939
[TBL] [Abstract][Full Text] [Related]
9. Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.
Bowen SR; Chappell RJ; Bentzen SM; Deveau MA; Forrest LJ; Jeraj R
Radiother Oncol; 2012 Oct; 105(1):41-8. PubMed ID: 22682748
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines.
Bradshaw TJ; Bowen SR; Deveau MA; Kubicek L; White P; Bentzen SM; Chappell RJ; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):787-95. PubMed ID: 25752393
[TBL] [Abstract][Full Text] [Related]
11. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
[TBL] [Abstract][Full Text] [Related]
13. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
16. Tumor hypoxia and microscopic diffusion capacity in brain tumors: a comparison of (62)Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging.
Hino-Shishikura A; Tateishi U; Shibata H; Yoneyama T; Nishii T; Torii I; Tateishi K; Ohtake M; Kawahara N; Inoue T
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1419-27. PubMed ID: 24719157
[TBL] [Abstract][Full Text] [Related]
17. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
18. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study.
Grassi I; Nanni C; Cicoria G; Blasi C; Bunkheila F; Lopci E; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2014 Jan; 39(1):e59-63. PubMed ID: 24097008
[TBL] [Abstract][Full Text] [Related]
20. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
